Cambridge Isotope Laboratories Appoints Todd Osiek, PhD, as Chief Science Officer

Osiek reports directly to the CEO, Cliff Caldwell. As CSO, Osiek is responsible for supporting operations development of best practices in safety and quality, working with sales and marketing on new-product development, and mapping out strategic directions and opportunities.

“Todd was the perfect addition to CIL’s team,” states Caldwell. “He comes to CIL with more than 20 years’ experience in the pharmaceutical industry, supporting various stages of development from discovery to marketed products.”

Osiek recently served as the Director of Analytical Chemistry, Research, at Mallinckrodt Pharmaceuticals, where his team handled all pipeline products, including technical support for method development, transfer, characterization, manufacturing technology transfers, and quality investigations.

“I was very excited when given the opportunity to join the CIL team,” adds Osiek. “I am thrilled to have the opportunity to work with the world leader in the stable isotope business. The future is bright for isotopes with their diverse applications and innovative uses. I look forward to working with CIL’s strong leadership team on the next phase of growth through continual expansion of our stable isotope product offerings, along with driving continuous improvement in our customer service and quality.”